News
CEO Dave Ricks Shares Lilly's Principles of COVID-19 Antibody Therapy Pricing and Access
View Story
Updates: Lilly's Global COVID-19 Response
View Story
Increasing Diversity in Clinical Trials
View Story
Lilly Statement Regarding NIH’s ACTIV-3 Clinical Trial
View Story
Overcoming Barriers to Biomarker Testing in Cancer
View Story
Lilly’s Commitment to Quality Manufacturing
View Story
October 29, 2020
Tags | Product
- Long-term and post-hoc analysis data show continued efficacy of Taltz in treating challenging body areas, including scalp, nails, palms and soles - INDIANAPOLIS , Oct. 29, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today it will share new Taltz ® (ixekizumab) data from
October 28, 2020
Tags | Product
INDIANAPOLIS , Oct. 28, 2020 /PRNewswire/ -- The New England Journal of Medicine has published data from the monotherapy arms of BLAZE-1, a Phase 2 study assessing the efficacy and safety of Eli Lilly and Company's (NYSE: LLY) bamlanivimab (LY-CoV555) – a neutralizing antibody – in the COVID-19
October 28, 2020
Tags | Product
- Initial agreement for 300,000 vials with potential for purchase of an additional 650,000 vials - Patients will have no out-of-pocket costs for the medication INDIANAPOLIS , Oct. 28, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today an initial agreement with the U.S.
- Revenue in the third quarter of 2020 increased 5 percent driven by volume growth of 9 percent, while on a year-to-date basis revenue increased 6 percent driven by volume growth of 12 percent. - Key growth products launched since 2014, consisting of Taltz, Trulicity, Verzenio, Jardiance,